A Critical Insight into the Clinical Translation of PD-1/PD-L1 Blockade Therapy in Clear Cell Renal Cell Carcinoma
- 90 Downloads
Purpose of Review
Targeting PD-1/PD-L1 immune checkpoints is a new therapeutic tool in patients with locally advanced and metastatic clear cell renal cell carcinoma (CCRCC). The purpose of this review is to offer clinicians an updated translational insight into the current status of a therapeutic alternative that may impact significantly patient’s life.
Immune checkpoint inhibition has recently demonstrated promising results in selected CCRCC patients with respect to tumor progression and survival. The decision to treat these patients with immune checkpoint inhibitors (ICI) relies on the immunohistochemical detection of PD-1/PD-L1 positivity in inflammatory cells in the tumor, which makes the role of the pathologist crucial, but clinical concern upon the reliability to use immunohistochemistry (IHC) to predict therapeutic response is increasing.
We review the state of the art of the immune checkpoint inhibition in CCRCC, from the basic science and its fundamentals to the daily application in clinical routine.
KeywordsClear cell renal cell carcinoma Immune checkpoint inhibition PD-1 PD-L1 Immunohistochemistry Sampling protocols Targeted therapy
This work has been partially funded by grants SAF2016-79847-R from Ministerio de Economía y Competitividad, Spain (to RP and JIL) and 239813 from The Norwegian Research Council, Norway (to CEN-X).
Compliance with Ethical Standards
Conflict of Interest
Caroline E. Nunes-Xavier, Javier C. Angulo, Rafael Pulido, and José I. López each declare no potential conflicts of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 6.•• Turajlic S, Xu H, Litchfield K, et al. Deterministic evolutionary trajectories influence primary tumor growth: TRACERx Renal. Cell. 2018;173:595–610. This paper describes for the first time 7 different evolutionary subtypes with impact on survival and exemplifies the complexity of intratumor heretogeneity of clear cell renal cell carcinoma. Google Scholar
- 7.•• Turajlic S, Xu H, Litchfield K, et al. Tracking renal cancer evolution reveals constrained routes to metastases: TRACERx Renal. Cell. 2018;173:581–94. Two different temporal patterns of metastases, early and late, are described after a genomic study in clear cell renal cell carcinoma. Google Scholar
- 13.• Turajlic S, Swanton C, Boshoff C. Kidney cancer: the next decade. J Exp Med. 2018;215: 2477–79. This short review offers an insight into the upcoming therapeutic strategies in renal cell carcinoma. Google Scholar
- 20.Latchman Y, Wood CR, Chernova T, Chaudhary D, Borde M, Chernova I, et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nature Immunol. 2001;2:261–8.Google Scholar
- 21.Greenwald RJ, Freeman GJ, Sharpe AH. The B7 family revisited. Ann Rev Immunol. 2005;23:515–48.Google Scholar
- 24.Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Ann Rev Immunol. 2008;26:677–704.Google Scholar
- 29.He XH, Liu Y, Xu LH, Zeng YY. Cloning and identification of two novel splice variants of human PD-L2. Acta Biochim Biophys Sinica. 2004;36:284–9.Google Scholar
- 30.He XH, Xu LH, Liu Y. Identification of a novel splice variant of human PD-L1 mRNA encoding an isoform-lacking Igv-like domain. Acta Pharmacol Sinica. 2005;26:462–8.Google Scholar
- 43.Tatli Dogan H, Kiran M, Bilgin B, Kiliçarslan A, Sendur MAN, Yalçin B, et al. Prognostic significance of the programmed death ligand 1 expression in clear cell renal cell carcinoma and correlation with the tumor microenvironment and hypoxia-inducible factor expression. Diagn Pathol. 2018;13:60.PubMedPubMedCentralGoogle Scholar
- 46.Patsoukis N, Brown J, Petkova V, Liu F, Li L, Boussiotis VA. Selective effects of PD-1 on Akt and Ras pathways regulate molecular components of the cell cycle and inhibit T cell proliferation. Sci Sign. 2012;5:ra46.Google Scholar
- 53.Dong P, Xiong Y, Yue J, Hanley SJB, Watari H. Tumor-intrinsic PD-L1 signaling in cancer initiation, development and treatment: beyond immune evasion. Front Oncol. 2018;8:385.Google Scholar
- 54.Gupta HB, Clark CA, Yuan B, Sareddy G, Pandeswara S, Padron AS, et al. Tumor cell-intrinsic PD-L1 promotes tumor-initiating cell generation and functions in melanoma and ovarian cancer. Sign Transduct Target Ther. 2016;1:16030.Google Scholar
- 56.Qiu XY, Hu DX, Chen WQ, et al. PD-L1 confers glioblastoma multiforme malignancy via Ras binding and Ras/Erk/EMT activation. Biochim Biophys Acta Mol basis Dis. 1864;2018:1754–69.Google Scholar
- 59.Iacovelli R, Nole F, Verri E, et al. Prognostic role of PD-L1 expression in renal cell carcinoma. A systematic review and meta-analysis. Targ Oncol. 2016;11:143–8.Google Scholar
- 64.• Choueiri TK, Motzer RJ. Systemic therapy for metastatic renal-cell carcinoma. N Eng J Med. 2017;376:354–66. Exhaustive review of the spectrum of systemic therapies available for patients with advanced renal cancer. Google Scholar
- 65.Flynn M, Pickering L, Larkin J, Turajlic S. Immune-checkpoint inhibitors in melanoma and kidney cancer: from sequencing to rational selection. Ther Adv Med Oncol. 2018;10:1–16.Google Scholar
- 71.• López JI, Cortés JM. A divide and conquer strategy in tumor sampling enhances detection of intratumor heterogeneity in pathology routine: a modeling approach in clear cell renal cell carcinoma. F1000Res. 2016;5:385. This paper describes an in silico approach to a new sampling method that improves intratumor heterogeneity detection in large tumors. Google Scholar
- 73.Ming D, Yang W. A divide and conquer strategy to improve diffusion sampling in generalized ensemble simulators. J Chem Phys. 2008;128:094106.Google Scholar
- 80.Munari E, Rossi G, Zamboni G, Lunardi G, Marconi M, Sommaggio M, et al. PD-L1 assays 22C3 and SP263 are not interchangeable in non-small cell lung cancer when considering clinically relevant cutoffs. An interclon evaluation by differently trained pathologists. Am J Surg Pathol. 2018;42:1384–9.PubMedGoogle Scholar
- 82.Wang C, Hahn E, Slodkowska E, Eskander A, Enepekides D, Higgins K, et al. Reproducibility of PD-L1 immunohistochemistry interpretation across various types of genitourinary and head/neck carcinomas, antibody clones, and tissue types. Hum Pathol. 2018;82:131–9. https://doi.org/10.1016/j.humpath.2018.07.024.CrossRefPubMedGoogle Scholar
- 83.Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single arm. Multicenter, phase 2 trial. Lancet. 2016;387:1909–20.PubMedPubMedCentralGoogle Scholar
- 84.•• Ross K, Jones RJ. Immune checkpoint inhibitors in renal cell carcinoma. Clin Sci. 2017;131:2627–42. Excellent review of the current status of immune checkpoint blockade in renal cell carcinoma. Google Scholar
- 85.• Özdemir BC, Siefker-Radtke AO, Campbell MT, Subudhi SK. Current and future applications of novel immunotherapies in urological oncology: a critical review of the literature. Eur Urol Focus. 2017, https://doi.org/10.1016/j.euf.2017.10.001. A review on the clinical data for immune checkpoint inhibition alone or in combination with other therapies for urologic malignancies.
- 87.•• Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373:1803–1813. This phase 3 randomized study demonstrated that patients with advanced renal cell carcinoma experienced longer survival with nivolumab treatment than with everolimus treatment after prior antiangiogenic treatment. Google Scholar
- 89.• Bedke J, Stühler V, Stenzl A, Brehmer B. Immunotherapy for kidney cancer: status quo and the future. Curr Opin Urol. 2018;28:8–14. Essential review on the immunotherapy for renal cell cancer, including both checkpoint inhibitors and vaccination strategies. Google Scholar
- 94.Rini BI, Stenzl A, Zdrojowy R, Kogan M, Shkolnik M, Oudard S, et al. IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicenter open-label, randomized, controlled phase 3 trial. Lancet Oncol. 2016;17:1599–611.PubMedGoogle Scholar
- 97.Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018;36:1714–68.Google Scholar
- 98.•• Shen X, Zhao B. Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis. BMJ. 2018;362:k3529. Meta-analysis that proves PD-L1 expression status is insufficient to determine patients that should be offered PD-1 or PD-L1 blockade therapy. Google Scholar
- 99.• Gibney GT, Weiner LM, Atkins MB. Predictive biomarkers for checkpoint inhibitor-based immunotherapy. Lancet Oncol. 2016;17:e542–51. Extensive review dealing with the pitfalls and possibilities to define accurate predictive biomarkers for checkpoint inhibition. Google Scholar